sargramostim at DC capture / migration; surveillance gathering, addressing throughput drop
sargramostim (myeloid lineage support) acts at the DC capture / migration; surveillance gathering step of the cancer-immunity cycle. The failure mode is throughput drop: factory's rate of work falls. Fewer units produced per unit time. Bottleneck somewhere on the production line.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the DC capture / migration; surveillance gathering step of the cancer-immunity cycle (capacitor regime, position P2), sargramostim acts via myeloid lineage support. The failure mode is throughput drop: factory's rate of work falls. Fewer units produced per unit time. Bottleneck somewhere on the production line. The intervention's regime-type class lines up with the position's regime, and failure_throughput_drop belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p2
- Failure modes
- failure_throughput_drop
Evidence at generation
"sargramostim" AND "cancer immunotherapy"
- PMID 34484202
Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
- PMID 21609205
Granulocyte-macrophage colony-stimulating factor increases the proportion of circulating dendritic cells after autologous but not after allogeneic hematopoietic stem cell transplantation.
Targets: —
Not found in ChEMBL: sargramostim (GM-CSF)
sargramostim cancer immunotherapy
- NCT05075122
Head and Neck Squamous Cell Carcinoma
Primary: Progression free survival rate
- NCT00019084
Breast Cancer
- NCT01909752
Carcinoma, Non-Small-Cell Lung
Primary: Identify the regimen that produces the strongest antibody response
- NCT00003199
Estrogen Receptor-negative Breast Cancer
Primary: Event-free Survival
- NCT02620865
Metastatic Pancreatic Adenocarcinoma
Primary: Median Overall Survival (OS)
Status timeline
- Draft2026-05-29T18:08:09Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system